Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction

被引:55
作者
Nirogi, Ramakrishna [1 ]
Kandikere, Vishwottarn [1 ]
Mudigonda, Koteshwara [1 ]
Komarneni, Prashanth [1 ]
Aleti, Raghupathi [1 ]
Boggavarapu, Rajeshkumar [1 ]
机构
[1] Suven Life Sci Ltd, Biopharmaceut Res, Serene Chambers, Hyderabad 500034, Andhra Pradesh, India
关键词
sitagliptin; DPP-4; inhibitor; liquid chromatography-tandem mass spectrometry; human plasma; pharmacokinetic study;
D O I
10.1002/bmc.926
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive high-performance liquid chromatography-positive ion electrospray tandem mass spectrometry method was developed and validated for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma. Following liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M + H](+) ions, m/z 408-235 for sitagliptin and m/z 310-148 for the internal standard. The assay exhibited a linear dynamic range of 0.1-250 ng/mL for sitagliptin in human plasma. The lower limit of quantification was 0.1 ng/mL with a relative standard deviation of less than 6%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. A run time of 2.0 min for each sample made it possible to analyze more than 300 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic studies. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:214 / 222
页数:9
相关论文
共 8 条
[1]   Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers [J].
Bergman, Arthur ;
Ebel, David ;
Liu, Fang ;
Stone, Julie ;
Wang, Amy ;
Zeng, Wei ;
Chen, Li ;
Dilzer, Stacy ;
Lasseter, Kenneth ;
Herman, Gary ;
Wagner, John ;
Krishna, Rajesh .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (06) :315-322
[2]   Review of sitagliptin phosphate: a novel treatment for type 2 diabetes [J].
Gallwitz, Baptist .
VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (02) :203-210
[3]   Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin [J].
Herman, G. A. ;
Stein, P. P. ;
Thornberry, N. A. ;
Wagner, J. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :761-767
[4]   Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses [J].
Herman, GA ;
Stevens, C ;
Van Dyck, K ;
Bergman, A ;
Yi, BM ;
De Smet, M ;
Snyder, E ;
Hilliard, D ;
Tanen, M ;
Tanaka, W ;
Wang, AQ ;
Zeng, W ;
Musson, D ;
Winchell, G ;
Davies, MJ ;
Ramael, S ;
Gottesdiener, KM ;
Wagner, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) :675-688
[5]   Sitagliptin [J].
Lyseng-Williamson, Katherine A. .
DRUGS, 2007, 67 (04) :587-597
[6]   Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS [J].
Matuszewski, BK ;
Constanzer, ML ;
Chavez-Eng, CM .
ANALYTICAL CHEMISTRY, 2003, 75 (13) :3019-3030
[7]   Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans [J].
Vincent, Stella H. ;
Reed, James R. ;
Bergman, Arthur J. ;
Elmore, Charles S. ;
Zhu, Bing ;
Xu, Shiyao ;
Ebel, David ;
Larson, Patrick ;
Zeng, Wei ;
Chen, Li ;
Dilzer, Stacy ;
Lasseter, Kenneth ;
Gottesdiener, Keith ;
Wagner, John A. ;
Herman, Gary A. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (04) :533-538
[8]   Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry [J].
Zeng, W ;
Musson, DG ;
Fisher, AL ;
Wang, AQ .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2006, 20 (08) :1169-1175